BioNTech counts on shift to cancer drugs after second quarter losses quadruple
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
BioNTech (BNTX) PT Lowered to $93 at Morgan Stanley
August 5, 2024 2:32 PM EDTMorgan Stanley analyst Terence Flynn lowered the price target on BioNTech (NASDAQ: BNTX) to $93.00 (from $101.00) while maintaining a Equalweight rating.
The analyst comments "BNTX reported a beat on revs but a miss on the bottom line due to higher OpEx. 2024 guidance was reiterated. Upcoming... More
